Pharmaceutical

BMS bags UK advanced melanoma win for Opdualag

The MHRA gave Bristol Myers Squibb’s Opdualag marketing authorisation for advanced melanoma as part of Project Orbis.

Dec 28, 2023 - 18:00
BMS bags UK advanced melanoma win for Opdualag
The MHRA gave Bristol Myers Squibb’s Opdualag marketing authorisation for advanced melanoma as part of Project Orbis.
Read the original article

Tags:

Previous Article

STAT+: 3 medtech trends to watch in 2024

Next Article

J&J jumps on ADC train, signs $1.7bn licensing deal with LegoChem

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Why Biogen is purposefully becoming more risk averse, according to Biogen’s CEO

Why Biogen is purposefully becoming more risk averse, a...

Oct 20, 2023

Out with the old, in with the new: Decoding biosimilar access with VPAG 

Out with the old, in with the new: Decoding biosimilar ...

Jan 31, 2024

STAT+: Complications spiked 25% in hospitals bought by private equity

STAT+: Complications spiked 25% in hospitals bought by ...

Dec 27, 2023